Literature DB >> 17361098

Sphingosine-1-phosphate metabolism and intestinal tumorigenesis: lipid signaling strikes again.

Babak Oskouian1, Julie Saba.   

Abstract

Sphingolipids are an evolutionary conserved class of membrane lipids synthesized by all eukaryotic cells. The biological functions of sphingolipids are diverse, encompassing structural roles through their participation in membrane lipid rafts, and informational roles via the involvement of their metabolites in signal transduction pathways. An important sphingolipid metabolite is sphingosine-1-phosphate (S1P), which acts through G protein-coupled receptors present on mammalian cells, thereby stimulating cell proliferation, angiogenesis and inhibiting apoptosis. The main enzyme responsible for S1P synthesis, sphingosine kinase 1 (Sphk1), behaves as an oncogene in experimental systems and is required for polyp enlargement in the Min mouse model of intestinal tumorigenesis. S1P is irreversibly degraded by S1P lyase (SPL), an enzyme that is highly expressed in enterocytes, where it is involved in metabolism of dietary sphingolipids. Forced expression of SPL sensitizes human cells to various stressful stimuli and enhances apoptotic cell death. SPL expression is induced in response to DNA damaging agents in a time- and concentration-dependent manner. On the other hand, SPL is downregulated in human colon cancers and in Min mouse adenomas compared to adjacent uninvolved tissues. These observations suggest that SPL, like Sphk1, may play a role in tumorigenesis. Added support for this notion comes from the fact that S1P-specific antibodies slow tumor progression and angiogenesis in murine xenograft and allograft models. Together, these recent studies have established a link between S1P signaling, metabolism and carcinogenesis that may have implications regarding colon cancer screening, dietary chemoprevention and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361098     DOI: 10.4161/cc.6.5.3903

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  29 in total

1.  The sphingolipid degradation product trans-2-hexadecenal forms adducts with DNA.

Authors:  Pramod Upadhyaya; Ashok Kumar; Hoe-Sup Byun; Robert Bittman; Julie D Saba; Stephen S Hecht
Journal:  Biochem Biophys Res Commun       Date:  2012-06-19       Impact factor: 3.575

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

Review 3.  PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism.

Authors:  Florence Bourquin; Guido Capitani; Markus Gerhard Grütter
Journal:  Protein Sci       Date:  2011-09       Impact factor: 6.725

4.  Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways.

Authors:  Shi-Quan Liu; Jie-An Huang; Meng-Bin Qin; Ying-Jie Su; Ming-Yu Lai; Hai-Xing Jiang; Guo-Du Tang
Journal:  Int J Colorectal Dis       Date:  2012-06-09       Impact factor: 2.571

5.  Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.

Authors:  Daniel L Worthley; Susan L Woods; Tamsin R M Lannagan; Young K Lee; Tongtong Wang; Jatin Roper; Mark L Bettington; Lochlan Fennell; Laura Vrbanac; Lisa Jonavicius; Roshini Somashekar; Krystyna Gieniec; Miao Yang; Jia Q Ng; Nobumi Suzuki; Mari Ichinose; Josephine A Wright; Hiroki Kobayashi; Tracey L Putoczki; Yoku Hayakawa; Simon J Leedham; Helen E Abud; Ömer H Yilmaz; Julie Marker; Sonja Klebe; Pratyaksha Wirapati; Siddhartha Mukherjee; Sabine Tejpar; Barbara A Leggett; Vicki L J Whitehall
Journal:  Gut       Date:  2018-04-17       Impact factor: 23.059

6.  Oral PEG 15-20 protects the intestine against radiation: role of lipid rafts.

Authors:  Vesta Valuckaite; Olga Zaborina; Jason Long; Martin Hauer-Jensen; Junru Wang; Christopher Holbrook; Alexander Zaborin; Kenneth Drabik; Mukta Katdare; Helena Mauceri; Ralph Weichselbaum; Millicent A Firestone; Ka Yee Lee; Eugene B Chang; Jeffrey Matthews; John C Alverdy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-15       Impact factor: 4.052

Review 7.  Targeting SphK1 as a new strategy against cancer.

Authors:  Dai Shida; Kazuaki Takabe; Dmitri Kapitonov; Sheldon Milstien; Sarah Spiegel
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

8.  Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis.

Authors:  Long Shuang Huang; Evgeny Berdyshev; Biji Mathew; Panfeng Fu; Irina A Gorshkova; Donghong He; Wenli Ma; Imre Noth; Shwu-Fan Ma; Srikanth Pendyala; Sekhar P Reddy; Tong Zhou; Wei Zhang; Steven A Garzon; Joe G N Garcia; Viswanathan Natarajan
Journal:  FASEB J       Date:  2013-01-11       Impact factor: 5.191

9.  Role of neutral ceramidase in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Toshihiko Kawamori; Masayuki Wada; Ashley J Snider; Jean-Philip Truman; Bill X Wu; Hideki Furuya; Christopher J Clarke; Agnieszka B Bialkowska; Amr Ghaleb; Vincent W Yang; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2016-09-08       Impact factor: 5.191

10.  Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion.

Authors:  Dai Shida; Xianjun Fang; Tomasz Kordula; Kazuaki Takabe; Sandrine Lépine; Sergio E Alvarez; Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.